ArticleJournal of family medicine and primary care2026
Severe dysgeusia and weight loss associated with terbinafine use: A case report.
Article in Journal of family medicine and primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Terbinafine is a widely used antifungal agent, with dysgeusia recognized as an uncommon and typically self-limited adverse effect. Severe or prolonged taste disturbance is exceedingly rare. We report the case of a 72-year-old woman who developed profound dysgeusia shortly after initiation of oral terbinafine for onychomycosis, manifesting as a persistent metallic taste, marked aversion to sweet foods, anorexia, and progressive unintentional weight loss. Despite early discontinuation of terbinafine, symptoms progressed, leading to electrolyte abnormalities and significant functional decline and prompting an extensive diagnostic evaluation to exclude malignancy and other serious etiologies. Supportive management following drug cessation resulted in gradual but incomplete recovery over several months. This case demonstrates that terbinafine-associated dysgeusia may be severe, prolonged, and clinically consequential in older adults, emphasizing the need for early recognition and prompt discontinuation to mitigate morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.